Global
About
Development milestones Mission&Vision Founder Research Achievement
Technical platform
Single domain antibody Five core technology platforms
Product pipeline
Business cooperation
Product Authorization Joint research and development External service
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2024-12-13
Congratulations to Dr. Wan Yakun, founder of Novamab for being selected as the "Pearl Leading Talent" for Pudong New Area in 2024
On December 7, 2024, the 2024 Pudong International Talent Port Forum was held at the Zhangjiang Science Hall. The forum officially unveiled and honored the recipients of the 'Pearl Plan' for P
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇
More
2023-07-04
CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum
CEO of Luoqi Biotechnology delivers a speech at the ACCESS CHINA Pharmaceuticals China Boston ForumA leading global enterprise in the research and development of innovative nano antibody drugsThe offl
More
2023-06-28
LQ036 IND application for COPD accepted by CDE
On June 27, 2023, Shanghai Novamab Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biological") announced that the IND application for COPD indication of LQ036 (LQ036
More
2023-05-25
Novamab presented the latest progress of 3 core assets at the ATS 2023 conference
On May 21, 2023, Dr. Wan Yakun, founder and chairman of Shanghai NovamabBiomedical Technology Co., Ltd., was invited to participate in the 2023 American Thoracic Society International Conference/Annua
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
A leading global enterprise in the research and development of innovative nano antibody drugsRecently, Dr. Wan Yakun, founder and chairman of Shanghai Novamab Biomedical Technology Co., Ltd., was invi
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
In 2022, among the top 20 best-selling drugs in the world, 8 are macromolecular drugs, and the proportion will be higher if COVID-19 is excluded. The two best-selling drugs Humira and Keytruda are ant
More
2023-01-14
洛启生物 祝您元旦快乐
描述为占位文字请客户提供描述为占位文字请客户提供，描述为占位文字请客户提供描述为占位文字请客户提供...
More
2023-01-06
Progress of new drugs I The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE
On January 6, 2023, the China National Drug Administration Drug Evaluation Center (CDE) announced that the application for clinical trial (IND) of LQ043H single-domain antibody aerosol, a core drug for the treatment of moderate and severe asthma of Shanghai Luoqi Biomedical Technology Co., Ltd., was officially approved (Notice No.: 2023LP00043). This is also another nano-antibody drug for respiratory diseases that was approved in Phase I of China's clinical trial after LQ036 in 2022.
More
2022-12-30
Annual Review I 2022 Wonderful Moments of Rocky Biology
In 2022, based on the clinical value orientation, Novamab will adhere to differential innovation. With the advantages of the core technology platform of nanoantibody, while focusing on the field of respiratory diseases, it will diversify its layout of high-potential markets such as autoimmunity, cancer, nuclear drugs, etc.
More
总计 54 123456